Clinical and molecular markers of vitiligo: a narrative review of early-stage insights into disease activity and treatment response
- 18 February 2026
- journal article
- review article
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 194 (6) , 1006-1023
Abstract
Vitiligo fluctuates between progressive and quiescent states, complicating decisions about when to intervene, how to select therapy and how to monitor response. In this review, we integrate bedside phenotypes with multilevel molecular readouts to summarize emerging evidence linking clinical signs and biologic signals to disease activity and treatment response in clinical studies. For staging, tool-free and standardized assessments such as Koebner phenomenon, confetti-like depigmentation, Wood’s lamp and dermoscopy provide visible clues associated with active disease. Measurements from blood, suction blister fluid and tissue offer complementary insights into local and systemic immune activation, suggesting how molecular signals may relate to progression. For stratification, factors such as age, lesion site, disease stability, comorbidities and dermoscopic border features have been tentatively associated with differential responses to therapies such as phototherapy or transplantation. Similarly, lower baseline levels of inflammatory, chemotactic and cytotoxic markers have been informally aligned with better outcomes in clinical studies. For monitoring, the response phase typically mirrors a reversal of progression: waning inflammatory signalling, reduced effector-cell burden and partial recovery of melanogenic programmes provide molecular parallels to clinical improvement. Across these domains, the interferon-γ–CXCL9/CXCL10–CD8+ T-cell axis emerges as the most recurrent immune signature, demonstrating reproducible associations with activity, prognosis and treatment response. Future work should prioritize harmonized definitions of disease activity, standardized sampling standards and multicentre validation of integrated biomarker panels. It is equally critical to determine whether proposed biomarker thresholds relate to clinically meaningful endpoints, thereby translating early-stage discoveries into reliable frameworks for staging, stratification and monitoring.Keywords
Funding Information
- National Natural Science Foundation of China (82473523)
- Natural Science Foundation of Shanghai (23ZR1408600)
- Clinical Research Plan of SHDC (SHDC22025306)
This publication has 116 references indexed in Scilit:
- The role of serum S100B and serum thyroid stimulating hormone levels in vitiligoArchives of Dermatological Research, 2025
- Ritlecitinib, a JAK3/TEC family kinase inhibitor, stabilizes active lesions and repigments stable lesions in vitiligoArchives of Dermatological Research, 2024
- Evaluation of vitamin D receptor gene polymorphisms (ApaI and TaqI) as risk factors of vitiligo and predictors of response to narrowband UVB phototherapyArchives of Dermatological Research, 2022
- Systemic CXCL10 is a predictive biomarker of vitiligo lesional skin infiltration, PUVA, NB-UVB and corticosteroid treatment response and outcomeArchives of Dermatological Research, 2021
- Differentially expressed microRNAs in peripheral blood mononuclear cells of non‐segmental vitiligo and their clinical significanceJournal of Clinical Laboratory Analysis, 2020
- Tacrolimus (FK506) ointment combined with Nb-UVB could activate both hair follicle (HF) and dermal melanocyte precursors in vitiligo: the first histopathological and clinical studyArchives of Dermatological Research, 2020
- Association of Clinical Markers With Disease Progression in Patients With Vitiligo From ChinaJAMA Dermatology, 2020
- Clinical Significance of Serum Soluble CD Molecules to Assess Disease Activity in VitiligoJAMA Dermatology, 2016
- Levels of TGF-β1 in serum and culture supernatants of CD4+CD25+ T cells from patients with non-segmental vitiligoArchives of Dermatological Research, 2011
- A comparative study of oxidant–antioxidant status in stable and active vitiligo patientsArchives of Dermatological Research, 2006